免疫血液学:医療機器パイプライン分析

◆英語タイトル:Immunohematology - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDT20FB0148
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年11月
◆ページ数:101
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Immunohematology – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Immunohematology – Medical Devices Pipeline Assessment, 2019″ provides an overview of Immunohematology currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunohematology pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Immunohematology under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Immunohematology and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Immunohematology under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Immunohematology Overview 6
3 Products under Development 7
3.1 Immunohematology – Pipeline Products by Stage of Development 7
3.2 Immunohematology – Pipeline Products by Segment 8
3.3 Immunohematology – Pipeline Products by Territory 9
3.4 Immunohematology – Pipeline Products by Regulatory Path 10
3.5 Immunohematology – Pipeline Products by Estimated Approval Date 11
4 Immunohematology – Pipeline Products under Development by Companies 12
4.1 Immunohematology Companies – Pipeline Products by Stage of Development 12
4.2 Immunohematology – Pipeline Products by Stage of Development 13
5 Immunohematology Companies and Product Overview 14
5.1 AbSorber AB Company Overview 14
5.1.1 AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 Alba Bioscience Limited Company Overview 15
5.2.1 Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 15
5.3 Amity University Company Overview 17
5.3.1 Amity University Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Arizona State University Company Overview 18
5.4.1 Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 18
5.5 Biofortuna Ltd Company Overview 19
5.5.1 Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 19
5.6 Grifols SA Company Overview 24
5.6.1 Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 24
5.7 Ortho-Clinical Diagnostics Inc Company Overview 25
5.7.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.8 Quotient Ltd Company Overview 27
5.8.1 Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
5.9 Transfusion & Transplantation Technologies (Inactive) Company Overview 30
5.9.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 30
6 Immunohematology- Recent Developments 35
6.1 Nov 04, 2019: Quotient reports second quarter fiscal 2020 financial results 35
6.2 Nov 01, 2019: Haemonetics reports 2nd quarter and 1st half fiscal 2020 results; raises fiscal 2020 adjusted operating margin and adjusted EPS guidance 37
6.3 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results 39
6.4 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results. 40
6.5 Oct 14, 2019: Biocare Medical appoints Nicolas Barthelemy as Executive Chairman 41
6.6 Sep 24, 2019: Theradiag announces improved results for H1 2019 41
6.7 Sep 12, 2019: Haemonetics Appoints Stewart W. Strong As President, Global Hospital 44
6.8 Sep 11, 2019: Bio-Rad files new lawsuit against 10X Genomics for Patent Infringement 45
6.9 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 45
6.10 Aug 06, 2019: Haemonetics reports 1st Quarter Fiscal 2020 results, updates Fiscal 2020 earnings guidance and launches operational excellence program 46
7 Appendix 98
7.1 Methodology 98
7.2 About GlobalData 101
7.3 Contact Us 101
7.4 Disclaimer 101

List of Tables
Table 1: Immunohematology - Pipeline Products by Stage of Development 8
Table 2: Immunohematology - Pipeline Products by Segment 9
Table 3: Immunohematology - Pipeline Products by Territory 10
Table 4: Immunohematology - Pipeline Products by Regulatory Path 11
Table 5: Immunohematology - Pipeline Products by Estimated Approval Date 12
Table 6: Immunohematology Companies - Pipeline Products by Stage of Development 13
Table 7: Immunohematology - Pipeline Products by Stage of Development 14
Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 15
Table 9: ABO Diagnostic Test - Product Status 15
Table 10: ABO Diagnostic Test - Product Description 15
Table 11: Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 16
Table 12: ALBAcyte O Adult i Cell Reagent - Product Status 16
Table 13: ALBAcyte O Adult i Cell Reagent - Product Description 16
Table 14: ALBAcyte O RhD VI Reagent Cells - Product Status 16
Table 15: ALBAcyte O RhD VI Reagent Cells - Product Description 17
Table 16: Amity University Pipeline Products & Ongoing Clinical Trials Overview 18
Table 17: Blood Group Testing Kit - Product Status 18
Table 18: Blood Group Testing Kit - Product Description 18
Table 19: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 19
Table 20: Blood Screening Immunosignaturing - Product Status 19
Table 21: Blood Screening Immunosignaturing - Product Description 19
Table 22: Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
Table 23: HemoPlex Kell Genotyping Kit - Product Status 20
Table 24: HemoPlex Kell Genotyping Kit - Product Description 20
Table 25: HemoPlex Kidd & Duffy Genotyping Kit - Product Status 21
Table 26: HemoPlex Kidd & Duffy Genotyping Kit - Product Description 21
Table 27: HemoPlex MNS Genotyping Kit - Product Status 21
Table 28: HemoPlex MNS Genotyping Kit - Product Description 21
Table 29: HemoPlex Multi Blood Group Genotyping Kit - Product Status 22
Table 30: HemoPlex Multi Blood Group Genotyping Kit - Product Description 22
Table 31: HemoPlex RHCE Screening Kit - Product Status 22
Table 32: HemoPlex RHCE Screening Kit - Product Description 22
Table 33: HemoPlex RHCE Variant Genotyping Kit - Product Status 23
Table 34: HemoPlex RHCE Variant Genotyping Kit - Product Description 23
Table 35: HemoPlex RHD & CE Genotyping Kit - Product Status 23
Table 36: HemoPlex RHD & CE Genotyping Kit - Product Description 23
Table 37: HemoPlex RHD Variant Genotyping Kit - Product Status 24
Table 38: HemoPlex RHD Variant Genotyping Kit - Product Description 24
Table 39: ThromboPlex HPA Screening Kit - Product Status 24
Table 40: ThromboPlex HPA Screening Kit - Product Description 25
Table 41: Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 26
Table 42: IH Blood Genotyping (D) Kit - Product Status 26
Table 43: IH Blood Genotyping (D) Kit - Product Description 26
Table 44: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 27
Table 45: ORTHO AutoVue - Rare Sera Assay - Product Status 27
Table 46: ORTHO AutoVue - Rare Sera Assay - Product Description 27
Table 47: ORTHO BioVue - Rare Sera Assay - Product Status 28
Table 48: ORTHO BioVue - Rare Sera Assay - Product Description 28
Table 49: Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 29
Table 50: Eluate Kit - Product Status 29
Table 51: Eluate Kit - Product Description 29
Table 52: Expanded IH Microarray - Product Status 30
Table 53: Expanded IH Microarray - Product Description 30
Table 54: IH Microarray Patient - Product Status 30
Table 55: IH Microarray Patient - Product Description 30
Table 56: Polyagglutionation Kit - Product Status 31
Table 57: Polyagglutionation Kit - Product Description 31
Table 58: Sensitivity Kit Anti-S, K, e, C - Product Status 31
Table 59: Sensitivity Kit Anti-S, K, e, C - Product Description 31
Table 60: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

List of Figures
Figure 1: Immunohematology - Pipeline Products by Stage of Development 7
Figure 2: Immunohematology - Pipeline Products by Segment 8
Figure 3: Immunohematology - Pipeline Products by Territory 9
Figure 4: Immunohematology - Pipeline Products by Regulatory Path 10
Figure 5: Immunohematology - Pipeline Products by Estimated Approval Date 11

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[免疫血液学:医療機器パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆